drugset
drugset / Trial / NCT00201669

A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma

NCT00201669 ↗

Phase 2 Completed 6 enrolled Ohio State University Comprehensive Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This study will determine the efficacy of clofarabine as measured by response rate in patients with aggressive non-Hodgkin's lymphoma

Timeline

Start
2004-10
Primary completion
2006-05
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 30 mg/m2 Intravenous

Indications

non-Hodgkin lymphoma